Compounds > alpha-methylmethionine
Page last updated: 2024-11-07

alpha-methylmethionine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID135729
CHEMBL ID49574
CHEBI ID191230
SCHEMBL ID162014
MeSH IDM0280967

Synonyms (26)

Synonym
methionine, 2-methyl-
ALPHA-METHYLMETHIONINE ,
2-methylmethionine
CHEMBL49574
562-48-1
(2s)-2-amino-2-methyl-4-methylsulanylbutanoic acid
CHEBI:191230
(2s)-2-amino-2-methyl-4-methylsulfanylbutanoic acid
59013-75-1
SCHEMBL162014
AB76378
(2s)-2-amino-2-methyl-4-(methylsulfanyl)butanoic acid
2-methyl-l-methionine
l-.alpha.-methylmethionine
l-isovaline, 4-(methylthio)-
JOJ65K4Z4S ,
(s)-(+)-2-methylmethionine
.alpha.-methyl-l-methionine
l-methionine, 2-methyl-
l-alpha-methylmethionine
alpha-methyl-l-methionine
unii-joj65k4z4s
(s)-2-amino-2-methyl-4-(methylthio)butanoic acid
Q27281610
l-isovaline,4-(methylthio)-(9ci)
(s)-2-amino-2-methyl-4-(methylthio)butanoicacid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
D-alpha-amino acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
S-adenosylmethionine synthase isoform type-2Rattus norvegicus (Norway rat)Km21,000.00005.00005.00005.0000AID107590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID230665Ratio of Vmax of normal tissue (M-T) form of rat methionine Adenosyltransferase to that of KM of normal tissue(M-T)form of rat methionine Adenosyltransferase1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Isozyme-specific enzyme inhibitors. 12. C- and N-methylmethionines as substrates and inhibitors of methionine adenosyltransferases of normal and hepatoma rat tissues.
AID107756Substrate activity as rate of conversion of [C14]-ATP to [C14]-Adomet in relation to KM value of methionine with M-T of rat methionine adenosyltransferase1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Isozyme-specific enzyme inhibitors. 12. C- and N-methylmethionines as substrates and inhibitors of methionine adenosyltransferases of normal and hepatoma rat tissues.
AID107911Substrate activity of compound (4 mM) measured as the rate of conversion of [C14]-ATP to [C14]-Adomet in relation to KM value of methionine rat Methionine adenosyltransferase II1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Isozyme-specific enzyme inhibitors. 12. C- and N-methylmethionines as substrates and inhibitors of methionine adenosyltransferases of normal and hepatoma rat tissues.
AID107585Compound (3 mM) was tested for the inhibition of conversion of [14C]methionine to [14C]-AdoMet by M-T (hepatoma tissue) of rat methionine adenosyltransferase1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Isozyme-specific enzyme inhibitors. 12. C- and N-methylmethionines as substrates and inhibitors of methionine adenosyltransferases of normal and hepatoma rat tissues.
AID107754Substrate level that produces half the maximal velocity(M-T) of rat methionine adenosyltransferase1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Isozyme-specific enzyme inhibitors. 12. C- and N-methylmethionines as substrates and inhibitors of methionine adenosyltransferases of normal and hepatoma rat tissues.
AID107590Substrate activity with normal tissue (M-T) form of rat methionine adenosyltransferase1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Isozyme-specific enzyme inhibitors. 12. C- and N-methylmethionines as substrates and inhibitors of methionine adenosyltransferases of normal and hepatoma rat tissues.
AID107770Compound (3 mM) was tested for the inhibition of conversion of [14C]methionine to [14C]AdoMet by rat Methionine adenosyltransferase II1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Isozyme-specific enzyme inhibitors. 12. C- and N-methylmethionines as substrates and inhibitors of methionine adenosyltransferases of normal and hepatoma rat tissues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (20.00)18.7374
1990's2 (40.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.74 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
methionine
Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.		3.0950aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
s-methylcysteine
S-methylcysteine: RN given refers to parent cpd without isomeric designation. S-methylcysteine : A cysteine derivative that is L-cysteine in which the hydrogen attached to the sulfur is replaced by a methyl group.		7.0510S-alkyl-L-cysteine zwitterion;
S-alkyl-L-cysteine		human urinary metabolite;
plant metabolite
deoxyglucose
Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.		1.9910
mevalonic acid
Mevalonic Acid: A dihydroxy monocarboxylic acid and precursor in the biosynthetic pathway known as the mevalonate pathway, which produces terpenes and steroids that are vital for diverse cellular functions.. mevalonic acid : A racemate composed of equimolar amounts of (R)- and (S)-mevalonic acid.. (R)-mevalonic acid : The (R)-enantiomer of mevalonic acid.		2103,5-dihydroxy-3-methylpentanoic acid
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		7.0510cysteiniumfundamental metabolite
fmrfamide
FMRFamide: A molluscan neuroactive peptide which induces a fast excitatory depolarizing response due to direct activation of amiloride-sensitive SODIUM CHANNELS. (From Nature 1995; 378(6558): 730-3)		1.9910
s-adenosylmethionine
(R)-S-adenosyl-L-methionine : An S-adenosyl-L-methionine that has R-configuration.. S-adenosyl-L-methionine zwitterion : A zwitterionic tautomer of S-adenosyl-L-methionine arising from shift of the proton from the carboxy group to the amino group.. (R)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has R-configuration; major species at pH 7.3.. (S)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has S-configuration; major species at pH 7.3.. S-adenosyl-L-methionine : A sulfonium compound that is the S-adenosyl derivative of L-methionine. It is an intermediate in the metabolic pathway of methionine.		210organic cation;
sulfonium compound		coenzyme;
cofactor;
human metabolite;
micronutrient;
Mycoplasma genitalium metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Experimental Hepatoma
[description not available]		01.9610
Anaplastic Astrocytoma
[description not available]		01.9910
Benign Neoplasms, Brain
[description not available]		01.9910
Anaplastic Oligodendroglioma
[description not available]		01.9910
Astrocytoma
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)		01.9910
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		01.9910
Oligodendroglioma
A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655)		01.9910